HC Wainwright Issues Negative Forecast for Alphatec Earnings

Posted by Brian Himes on Aug 11th, 2026

Alphatec Holdings, Inc. (NASDAQ:ATEC – Free Report) – Analysts at HC Wainwright cut their FY2027 EPS estimates for Alphatec in a research report issued on Wednesday, August 5th. HC Wainwright analyst S. Lee now anticipates that the medical technology company will post earnings of $0.47 per share for the year, down from their prior estimate of $0.59. HC Wainwright has a “Buy” rating and a $24.00 price objective on the stock. The consensus estimate for Alphatec’s current full-year earnings is ($0.44) per share. HC Wainwright also issued estimates for Alphatec’s FY2030 earnings at $1.19 EPS.

ATEC has been the topic of a number of other research reports. Piper Sandler reissued an “overweight” rating and issued a $14.00 target price (down from $25.00) on shares of Alphatec in a research report on Wednesday, May 6th. Wall Street Zen cut shares of Alphatec from a “buy” rating to a “hold” rating in a research note on Sunday, July 12th. Canaccord Genuity Group cut their price objective on shares of Alphatec from $25.00 to $23.00 and set a “buy” rating on the stock in a research report on Wednesday, May 6th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Alphatec in a research report on Monday, August 3rd. Finally, Stephens started coverage on shares of Alphatec in a research report on Thursday, July 23rd. They set an “overweight” rating and a $15.00 price target on the stock. Thirteen research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, Alphatec presently has an average rating of “Moderate Buy” and an average price target of $17.40.

Read Our Latest Research Report on ATEC

Alphatec Trading Up 1.9%

ATEC opened at $9.49 on Tuesday. The stock has a market capitalization of $1.47 billion, a P/E ratio of -13.37 and a beta of 0.85. The company has a current ratio of 1.89, a quick ratio of 1.07 and a debt-to-equity ratio of 40.35. Alphatec has a 12 month low of $6.82 and a 12 month high of $23.29. The firm’s fifty day simple moving average is $8.83 and its 200 day simple moving average is $10.60.

Alphatec (NASDAQ:ATEC – Get Free Report) last issued its quarterly earnings data on Tuesday, August 4th. The medical technology company reported $0.07 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.07. Alphatec had a negative net margin of 13.49% and a negative return on equity of 6,752.24%. The company had revenue of $213.51 million during the quarter, compared to the consensus estimate of $211.26 million. During the same quarter in the prior year, the firm earned $0.02 earnings per share. The firm’s revenue was up 15.1% compared to the same quarter last year.

Insider Activity at Alphatec

In other news, Director Karen K. Mcginnis sold 6,050 shares of the company’s stock in a transaction that occurred on Thursday, June 11th. The stock was sold at an average price of $8.01, for a total value of $48,460.50. Following the transaction, the director owned 94,671 shares of the company’s stock, valued at approximately $758,314.71. This represents a 6.01% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, General Counsel Tyson Eliot Marshall sold 8,168 shares of the company’s stock in a transaction on Wednesday, August 5th. The shares were sold at an average price of $9.65, for a total value of $78,821.20. Following the completion of the transaction, the general counsel directly owned 630,398 shares in the company, valued at approximately $6,083,340.70. This represents a 1.28% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Company insiders own 13.48% of the company’s stock.

Institutional Investors Weigh In On Alphatec

Large investors have recently added to or reduced their stakes in the stock. Vanguard Group Inc. increased its stake in Alphatec by 1.0% during the 4th quarter. Vanguard Group Inc. now owns 6,883,626 shares of the medical technology company’s stock worth $144,831,000 after acquiring an additional 68,568 shares during the period. Morgan Stanley grew its holdings in shares of Alphatec by 22.0% during the 4th quarter. Morgan Stanley now owns 4,340,936 shares of the medical technology company’s stock worth $91,333,000 after purchasing an additional 784,191 shares in the last quarter. State Street Corp grew its holdings in shares of Alphatec by 6.4% during the 4th quarter. State Street Corp now owns 2,889,240 shares of the medical technology company’s stock worth $60,790,000 after purchasing an additional 174,287 shares in the last quarter. Geode Capital Management LLC increased its position in shares of Alphatec by 1.2% in the fourth quarter. Geode Capital Management LLC now owns 2,828,026 shares of the medical technology company’s stock worth $59,511,000 after purchasing an additional 32,465 shares during the period. Finally, Bank of America Corp DE raised its stake in Alphatec by 26.9% in the first quarter. Bank of America Corp DE now owns 2,560,971 shares of the medical technology company’s stock valued at $27,863,000 after purchasing an additional 543,059 shares in the last quarter. Institutional investors and hedge funds own 66.35% of the company’s stock.

Alphatec Company Profile

(Get Free Report)

Alphatec Holdings, Inc (NASDAQ: ATEC) is a medical technology company focused on the design, development and commercialization of products for the surgical correction of degenerative spinal conditions. The company’s portfolio centers on interbody implants, biologics, fixation devices and surgical planning tools intended to improve patient outcomes in spinal fusion procedures. Alphatec’s flagship offerings include customizable interbody cages, bone graft materials and specialized instrumentation designed for minimally invasive and open spinal surgeries.

Founded as Alphatec Spine in 1985 and rebranded as Alphatec Holdings in 2018, the company has grown from a single-product organization into a multi-platform innovator in the spine market.